OYST Oyster Point Pharma

Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth

Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth
EN
08/10/2020

Underlying

OYSTOyster Point Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oyster Point Pharma

 PRESS RELEASE
Free
OYST Oyster Point Ph...

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq List...

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock t...

December 2, 2022 1 EN
 PRESS RELEASE
Free
OYST Oyster Point Ph...

Oyster Point Pharma Reports Third Quarter 2022 Financial Results and R...

Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3’22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covered...

November 10, 2022 1 EN
 PRESS RELEASE
Free
OYST Oyster Point Ph...

Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical...

Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), today announced that it has entered into a definitive agreement under which Viatris Inc. (Nasdaq: VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused o...

November 7, 2022 1 EN
 PRESS RELEASE
Free
OYST Oyster Point Ph...

Oyster Point Pharma To Report Third Quarter 2022 Financial Results On ...

Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022 Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022, after the market close. The announcement will be followe...

November 2, 2022 1 EN
 PRESS RELEASE
Free
OYST Oyster Point Ph...

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq List...

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 14,400 shares of common stock t...

November 2, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch